Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jul;8(7):801-13.
doi: 10.1586/eri.10.60.

New drugs and regimens for treatment of TB

Eric Leibert  1 , William N Rom
Affiliations
Review

New drugs and regimens for treatment of TB

Eric Leibert et al. Expert Rev Anti Infect Ther. 2010 Jul.

Abstract

Tools for effective TB control have been available for years. Case finding, active medications, case management and directly observed therapy are the foundations for the management of TB. The current TB epidemic, centered in resource-limited settings is fueled by the HIV-1 epidemic. Lack of ability to diagnose and treat drug-resistant TB has led to development of more extensive patterns of resistance. Among the currently available drugs, there is reason to hope that rifamycins paired with fluoroquinolones will lead to shorter treatment regimens for drug-susceptible TB. As the result of novel public-private collaborations and investments of resources, new drugs are being developed. These include TMC207, already shown to have activity early in the treatment of multidrug-resistant TB and others that are likely to be active against persistor organisms, and have the prospect to dramatically shorten treatment courses for active and latent TB. Given that these drugs have novel mechanisms of action, combinations have the prospect to be highly active even against multidrug-resistant organisms.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no other relevant affiliations, or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

    1. Hershkovitz I, Donoghue HD, Minnikin DE, et al. Detection and molecular characterization of 9,000-year-old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean. PLoS One. 2008;3(10):e3426. - PMC - PubMed
    1. Zink A, Haas CJ, Reischl U, Szeimies U, Nerlich AG. Molecular analysis of skeletal tuberculosis in an ancient Egyptian population. J. Med. Microbiol. 2001;50(4):355–366. - PubMed
    1. Formicola V, Milanesi Q, Scarsini C. Evidence of spinal tuberculosis at the beginning of the Fourth Millennium BC from Arene Candide cave (Liguria, Italy) Am. J. Phys. Anthropol. 1987;72(1):1–6. - PubMed
    1. Bates JH, Stead WW. The history of tuberculosis as a global epidemic. Med. Clin. North Am. 1993;77(6):1205–1217. - PubMed
    1. Bunyan J, Forrest JF, Sharrock R. The Life and Death of Mr. Badman: Presented to the World in a Familiar Dialogue Between Mr. Wiseman and Mr. Attentive. Oxford, UK: Oxford University Press; 1988.

Websites

    1. CDC. Managing drug interactions in the treatment of HIV-related tuberculosis. 2007 www.cdc.gov/tb/TB_HIV_Drugs/default.htm.
    1. Global Alliance for TB Drug Development. www.tballiance.org/about/donors.php.
    1. Global Alliance for TB Drug Development. www.tballiance.org/new/portfolio.php.
    1. Clinical Trials.gov A service of the US National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00664313.
    1. TB Antimicrobial Acquisition and Coordinating Facility global discovery program for novel anti-tuberculosis drugs. www.taacf.org/about-TAACF.htm.

Publication types

MeSH terms